← All Meiragtx Holdings PLC filings

Meiragtx Holdings PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
MGTX
Meiragtx Holdings PLC
10-K: MeiraGTx posts $81M revenue on Lilly deal
MeiraGTx reported $81.4M in 2025 revenue driven by a $75M Lilly upfront, narrowed its net loss to $114.2M, secured FDA Breakthrough for its xerostomia gene therapy, and extended liquidity into H2 2027 pending a $200M Hologen collaboration closing in Q2 2026.
NASDAQ
MGTX
Meiragtx Holdings PLC
10-K: MeiraGTx Holdings PLC Announces 2024 Financial Results and Provides Business Update
MeiraGTx Holdings PLC reports its financial results for the year ended December 31, 2024, highlighting progress in clinical programs and strategic collaborations.
NASDAQ
MGTX
Meiragtx Holdings PLC
10-K: Janssen Acquires MeiraGTx's RPGR Program in Deal Worth Up to $415 Million
Janssen Pharmaceuticals acquires MeiraGTx's RPGR program for up to $415 million, including an upfront payment and potential milestone payments.